This page shows the latest tasimelteon news and features for those working in and with pharma, biotech and healthcare.
Vanda Pharmaceuticals got the go-ahead for Hetlioz (tasimelteon) for the treatment of non-24-hour sleep wake disorder in totally blind adults - which was approved in the US last year -
Vanda Pharmaceuticals is now allowed to market its drug Hetlioz (tasimelteon) to treat a condition called non-24-hour sleep-wake disorder, which causes problems in the sleep cycle of blind
A Food Drug and Administration (FDA) advisory committee voted unanimously to recommend approval of Vanda Pharmaceuticals' Hetlioz (tasimelteon) for non-24-hour disorder (N24) in the totally blind. ... Tasimelteon acts on melatonin MT1/MT2 receptors and
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Valid Insight is an award-winning pharmaceutical global market access consultancy....